Abound Bio

We are a biotechnology company with operations in Europe and the U.S. dedicated to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules, CAR-T therapies, and biologics in oncology and immunology. With capabilities from lab to patient, including a decentralized, point-of-care CAR-T manufacturing network, we are committed to challenging the status quo and delivering results for our patients, employees and shareholders. 

Galapagos

NewAmsterdam Pharma is a competitor of Galapagos NV in the biotechnology sector, focusing on drug discovery and development.

NewAmsterdam Pharma (NAMS)

Syndax Pharmaceuticals competes with Galapagos NV in the biotechnology industry, particularly in the development of small molecule medicines.

Syndax Pharmaceuticals (SNDX)

Agios Pharmaceuticals is a competitor of Galapagos NV in the biotechnology sector, with a focus on drug discovery and development.

Agios Pharmaceuticals (AGIO)

Edgewise Therapeutics competes with Galapagos NV in the biotechnology industry, particularly in the discovery and development of small molecule medicines.

Edgewise Therapeutics

Adaptimmune Therapeutics is a competitor of Galapagos NV in the biotechnology sector, focusing on novel modes of action for small molecule medicines.

Adaptimmune Therapeutics

Argenx competes with Galapagos NV in the biotechnology industry, particularly in the development of small molecule medicines.

Argenx

Axsome Therapeutics is a competitor of Galapagos NV in the biotechnology sector, with a focus on drug discovery and development.

Axsome Therapeutics

BioArctic competes with Galapagos NV in the biotechnology industry, particularly in the discovery and development of small molecule medicines.

BioArctic

GVK BIO is a competitor of Galapagos NV in the biotechnology sector, focusing on drug discovery and development.

GVK BIO

Idorsia competes with Galapagos NV in the biotechnology industry, particularly in the development of small molecule medicines.

Idorsia

OMass is a competitor of Galapagos NV in the biotechnology sector, with a focus on drug discovery and development.

OMass

Octopus competes with Galapagos NV in the biotechnology industry, particularly in the discovery and development of small molecule medicines.

Octopus

Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. The company's pipeline includes a range of Phase 1 to Phase 3 clinical programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis, and other indications.

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Galapagos NV

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 15, 2024 10:37 AM	0f5f1488
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 15, 2024 10:37 AM	bc2bba0b
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:GLPG

Galapagos NV

Market Cap

1.73B

Beta: -

Volume Today

190

Avg: -